These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9292)

  • 1. Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. I. Relationship between plasma concentration and adrenergic beta-receptor blockade.
    Collste P; Haglund K; Frisk-Holmberg M; Rawlins MD
    Eur J Clin Pharmacol; 1976 Jun; 10(2):85-8. PubMed ID: 9292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II. Relationship to its effect on blood pressure and plasma renin activity.
    Collste P; Haglund K; Frisk-Holmberg M; Orme ML; Rawlins MD; Ostman J
    Eur J Clin Pharmacol; 1976 Jun; 10(2):89-95. PubMed ID: 964292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alprenolol and hydralazine on plasma renin concentration in patients with arterial hypertension.
    Pedersen EB; Kornerup HJ
    Acta Med Scand; 1975 Nov; 198(5):379-83. PubMed ID: 1199814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of 4-hydroxy-alprenolol to adrenergic beta receptor blockade of alprenolol.
    Collste P; Borg KO; Aström H; von Bahr C
    Clin Pharmacol Ther; 1979 Apr; 25(4):416-22. PubMed ID: 34497
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma renin concentration in essential hypertension during beta-adrenergic blockade and vasodilator therapy.
    Pedersen EB; Kornerup HJ
    Eur J Clin Pharmacol; 1977 Oct; 12(2):93-6. PubMed ID: 923630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of beta-adrenergic blockade with alprenolol on ST-segment depression and circulatory dynamics during exercise in patients with effort angina.
    Bailey IK; Anderson SD; Rozea PJ; Bernstein L; Nyberg G; Korner PI
    Am Heart J; 1976 Oct; 92(4):416-26. PubMed ID: 961582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between plasma aldosterone concentration and plasma potassium in patients with essential hypertension during alprenolol treatment.
    Pedersen EB; Kornerup HJ
    Acta Med Scand; 1976; 200(4):263-7. PubMed ID: 983793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state plasma concentrations of alprenolol in man.
    Rawlins MD; Collste P; Frisk-Holmberg M; Lind M; Ostman J; Sjöqvist F
    Eur J Clin Pharmacol; 1974 Aug; 7(5):353-6. PubMed ID: 4419005
    [No Abstract]   [Full Text] [Related]  

  • 9. Twice-daily pindolol and alprenolol in essential hypertension of moderate severity.
    Hartikainen M; Heikkilä J
    Ann Clin Res; 1976 Apr; 8(2):85-92. PubMed ID: 779590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of prolonged beta-blockade on energy metabolism and adrenergic responses in the rat.
    Harri MN
    Med Biol; 1977 Oct; 55(5):268-76. PubMed ID: 592903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of metoprolol --a new selective adrenergic beta1-receptor blocking agent-- in mild hypertension.
    Bengtsson C
    Acta Med Scand; 1976; 199(1-2):65-70. PubMed ID: 3093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-adrenergic blockade in hypertension.
    Hansson L; Werkö L
    Am Heart J; 1977 Mar; 93(3):394-402. PubMed ID: 14497
    [No Abstract]   [Full Text] [Related]  

  • 13. QT time in patients treated with alprenolol or placebo after myocardial infarction.
    Nyberg G; Vedin A; Wilhelmsson C
    Br Heart J; 1979 Apr; 41(4):452-5. PubMed ID: 380606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.
    Seideman P; Borg KO; Haglund K; Von Bahr C
    Br J Clin Pharmacol; 1987 Mar; 23(3):267-71. PubMed ID: 3567041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol.
    Collste P; Seideman P; Borg KO; Haglund K; von Bahr C
    Clin Pharmacol Ther; 1979 Apr; 25(4):423-7. PubMed ID: 428186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glomerular filtration rate and renal plasma flow in patients with essential hypertension before and after treatment with alprenolol.
    Pedersen EB
    Acta Med Scand; 1975 Nov; 198(5):365-71. PubMed ID: 1199812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension.
    von Bahr C; Collste P; Frisk-Holmberg M; Haglund K; Jorfelt L; Orme M; Ostman J; Sjoqvist F
    Clin Pharmacol Ther; 1976 Aug; 20(2):130-7. PubMed ID: 7373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of beta adrenergic blocking agents (alprenolol and propranolol) in essential hypertension.
    Nik-Akhtar B; Rashed MA; Khakpour M
    Angiology; 1975 Apr; 26(4):339-43. PubMed ID: 1119734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria.
    Surman AJ; Doggrell SA
    J Cardiovasc Pharmacol; 1993 Jan; 21(1):35-9. PubMed ID: 7678677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.